Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
According to a small multi-center, phase II trial reported in NEJM, an investigational targeted drug for some patients with metastatic thyroid cancer can induce partial responses. References and…
The tumor-derived vaccine vitespen (Oncophage) does not prevent renal-cell carcinoma recurrence or improve survival despite promising early results. References and Resources Wood C, Srivastava P, Bukowski R, et…
Andrea L. Looney, DVM, DiP/ACVA, Senior Lecturer, Section of Anesthesiology, Cornell University College of Veterinary Medicine, Ithaca, NY, discusses behavioral and physiological signs of pain in animals. Sponsored…
Charles Young, MD, Editor, BMJ Clinical Evidence, Editor in Chief of BMJ In Practice, discusses evidence-based information in medicine. Doctor’s Digest single topic reference guides provide physicians with…
John C. Herr, PhD, Professor of Cell Biology, Center Director, Department of Cell Biology, University of Virginia Health System, discusses sperm protein 10 (SP-10), which is used to…
Jaime Landman, MD, Minimally Invasive Urology, Columbia University Medical Center, New York, NY, discusses his thoughts on the advantages of minimally invasive surgical procedures. References and Resources Ukimura…
Jaime Landman, MD, Minimally Invasive Urology, Columbia University Medical Center, New York, NY, discusses open and laparoscopic partial nephrectomies. References and Resources Young JG, Luscombe CJ, Lynch C,…
Jaime Landman, MD, Minimally Invasive Urology, Columbia University Medical Center, New York, NY, discusses his thoughts on minimally invasive surgery in urology. References and Resources Raman JD, Cadeddu…
American women want a health care system in which they and their families can conveniently obtain preventive services, see their personal physicians the day they become sick, and…
According to results of a multi-center, placebo-controlled phase IIb trial, patients treated with laquinimod, a new type of immumodulatory agent for relapsing-remitting MS, had a 40% reduction in…
